IGM Biosciences (IGMS) Stock Forecast, Price Target & Predictions
IGMS Stock Forecast
IGM Biosciences stock forecast is as follows: an average price target of $25.00 (represents a 168.53% upside from IGMS’s last price of $9.31) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
IGMS Price Target
The average price target for IGM Biosciences (IGMS) is $25.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $37.00 to $12.00. This represents a potential 168.53% upside from IGMS's last price of $9.31.
IGMS Analyst Ratings
According to 2 Wall Street analysts, IGM Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for IGMS stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
IGM Biosciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 15, 2024 | Robert Driscoll | Wedbush | $25.00 | $8.72 | 186.70% | 168.53% |
| Aug 14, 2024 | Michael Ulz | Morgan Stanley | $12.00 | $8.72 | 37.61% | 28.89% |
| May 09, 2024 | Brian Abrahams | RBC Capital | $20.00 | $9.34 | 114.13% | 114.82% |
| Aug 23, 2022 | - | Truist Financial | $37.00 | $19.53 | 89.45% | 297.42% |
| Jun 20, 2022 | Joel Beatty | Robert W. Baird | $31.00 | $15.24 | 103.41% | 232.98% |
| Mar 30, 2022 | Asthika Goonewardene | Truist Financial | $74.00 | $25.85 | 186.27% | 694.84% |
The latest IGM Biosciences stock forecast, released on Aug 15, 2024 by Robert Driscoll from Wedbush, set a price target of $25.00, which represents a 186.70% increase from the stock price at the time of the forecast ($8.72), and a 168.53% increase from IGMS last price ($9.31).
IGM Biosciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 2 | 3 |
| Avg Price Target | $18.50 | $18.50 | $19.00 |
| Last Closing Price | $9.31 | $9.31 | $9.31 |
| Upside/Downside | 98.71% | 98.71% | 104.08% |
In the current month, the average price target of IGM Biosciences stock is $18.50, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 98.71% increase as opposed to IGM Biosciences's last price of $9.31. This month's average price target is down 0.00% compared to last quarter, and down -2.63% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 05, 2024 | Wedbush | Buy | Buy | Hold |
| Sep 05, 2024 | RBC Capital | Underperform | Underperform | Hold |
| Aug 15, 2024 | Wedbush | Neutral | Neutral | Hold |
| Aug 15, 2024 | RBC Capital | Underperform | Underperform | Hold |
| Aug 15, 2024 | Wedbush | Outperform | Outperform | Hold |
| Aug 14, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| May 24, 2024 | RBC Capital | Underperform | Underperform | Hold |
| May 24, 2024 | Wedbush | Neutral | Neutral | Hold |
| May 09, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Apr 18, 2024 | Wedbush | Neutral | Neutral | Hold |
IGM Biosciences's last stock rating was published by Wedbush on Sep 05, 2024. The company gave IGMS a "Buy" rating, the same as its previous rate.
IGM Biosciences Financial Forecast
IGM Biosciences Revenue Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $509.00K | $448.00K | $522.00K | $372.00K | $331.00K | - |
| Avg Forecast | $73.37M | $63.13M | $52.96M | $45.54M | $40.14M | $25.85M | $6.79M | $6.79M | $1.13M | $1.13M | $1.13M | $1.13M | $168.75K | $228.13K | $54.31M | $740.63K | $699.50K | $838.33K | $797.00K | $1.48M | $304.78K | $261.00K | $51.88M |
| High Forecast | $73.37M | $63.13M | $52.96M | $45.54M | $40.14M | $25.85M | $6.79M | $6.79M | $1.13M | $1.13M | $1.13M | $1.13M | $168.75K | $356.44K | $54.31M | $740.63K | $1.12M | $838.33K | $797.00K | $1.48M | $304.78K | $261.00K | $51.88M |
| Low Forecast | $73.37M | $63.13M | $52.96M | $45.54M | $40.14M | $25.85M | $6.79M | $6.79M | $1.13M | $1.13M | $1.13M | $1.13M | $168.75K | $92.67K | $54.31M | $740.63K | $368.16K | $838.33K | $797.00K | $1.48M | $304.78K | $261.00K | $51.88M |
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.61% | 0.56% | 0.35% | 1.22% | 1.27% | - |
IGM Biosciences's average Quarter revenue forecast for Dec 23 based on 7 analysts is $699.50K, with a low forecast of $368.16K, and a high forecast of $1.12M. IGMS's average Quarter revenue forecast represents a 37.43% increase compared to the company's last Quarter revenue of $509.00K (Sep 23).
IGM Biosciences EBITDA Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-66.76M | $-68.21M | $-61.71M | $-56.26M | $-59.00M | - |
| Avg Forecast | $14.67M | $12.63M | $10.59M | $9.11M | $8.03M | $5.17M | $1.36M | $1.36M | $226.67K | $226.67K | $226.67K | $226.67K | $33.75K | $45.62K | $10.86M | $148.12K | $139.90K | $167.67K | $159.40K | $296.00K | $60.95K | $52.20K | $10.38M |
| High Forecast | $14.67M | $12.63M | $10.59M | $9.11M | $8.03M | $5.17M | $1.36M | $1.36M | $226.67K | $226.67K | $226.67K | $226.67K | $33.75K | $71.29K | $10.86M | $148.12K | $223.84K | $167.67K | $159.40K | $296.00K | $60.95K | $52.20K | $10.38M |
| Low Forecast | $14.67M | $12.63M | $10.59M | $9.11M | $8.03M | $5.17M | $1.36M | $1.36M | $226.67K | $226.67K | $226.67K | $226.67K | $33.75K | $18.53K | $10.86M | $148.12K | $73.63K | $167.67K | $159.40K | $296.00K | $60.95K | $52.20K | $10.38M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -398.17% | -427.91% | -208.48% | -923.04% | -1130.35% | - |
undefined analysts predict IGMS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than IGM Biosciences's previous annual EBITDA (undefined) of $NaN.
IGM Biosciences Net Income Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-61.99M | $-64.42M | $-59.31M | $-48.20M | $-55.56M | - |
| Avg Forecast | $-3.50M | $-7.58M | $-11.62M | $-14.45M | $-15.45M | $-22.95M | $-36.70M | $-36.04M | $-40.49M | $-39.89M | $-39.58M | $-40.94M | $-46.87M | $-47.54M | $-2.46M | $-48.67M | $-61.11M | $-68.14M | $-84.79M | $-79.58M | $-92.34M | $-84.34M | $-34.00M |
| High Forecast | $-3.50M | $-7.58M | $-11.62M | $-14.45M | $-15.45M | $-22.95M | $-36.70M | $-36.04M | $-40.49M | $-39.89M | $-39.58M | $-40.94M | $-46.87M | $-44.10M | $-2.46M | $-48.67M | $-50.15M | $-68.14M | $-84.79M | $-79.58M | $-92.34M | $-84.34M | $-34.00M |
| Low Forecast | $-3.50M | $-7.58M | $-11.62M | $-14.45M | $-15.45M | $-22.95M | $-36.70M | $-36.04M | $-40.49M | $-39.89M | $-39.58M | $-40.94M | $-46.87M | $-50.41M | $-2.46M | $-48.67M | $-66.29M | $-68.14M | $-84.79M | $-79.58M | $-92.34M | $-84.34M | $-34.00M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.91% | 0.76% | 0.75% | 0.52% | 0.66% | - |
IGM Biosciences's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. IGMS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
IGM Biosciences SG&A Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $12.51M | $12.98M | $13.00M | $11.62M | $12.66M | - |
| Avg Forecast | $1.07B | $922.06M | $773.54M | $665.12M | $586.34M | $377.58M | $99.18M | $99.18M | $16.55M | $16.55M | $16.55M | $16.55M | $2.46M | $3.33M | $793.33M | $10.82M | $10.22M | $12.25M | $11.64M | $21.62M | $4.45M | $3.81M | $757.85M |
| High Forecast | $1.07B | $922.06M | $773.54M | $665.12M | $586.34M | $377.58M | $99.18M | $99.18M | $16.55M | $16.55M | $16.55M | $16.55M | $2.46M | $5.21M | $793.33M | $10.82M | $16.35M | $12.25M | $11.64M | $21.62M | $4.45M | $3.81M | $757.85M |
| Low Forecast | $1.07B | $922.06M | $773.54M | $665.12M | $586.34M | $377.58M | $99.18M | $99.18M | $16.55M | $16.55M | $16.55M | $16.55M | $2.46M | $1.35M | $793.33M | $10.82M | $5.38M | $12.25M | $11.64M | $21.62M | $4.45M | $3.81M | $757.85M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.02% | 1.12% | 0.60% | 2.61% | 3.32% | - |
IGM Biosciences's average Quarter SG&A projection for Dec 23 is $10.22M, based on 7 Wall Street analysts, with a range of $5.38M to $16.35M. The forecast indicates a -18.31% fall compared to IGMS last annual SG&A of $12.51M (Sep 23).
IGM Biosciences EPS Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.00 | $-0.00 | $-1.33 | $-1.09 | $-1.26 | - |
| Avg Forecast | $-0.06 | $-0.13 | $-0.19 | $-0.24 | $-0.26 | $-0.38 | $-0.61 | $-0.60 | $-0.67 | $-0.66 | $-0.66 | $-0.68 | $-0.78 | $-0.79 | $-0.04 | $-0.81 | $-1.01 | $-1.13 | $-1.40 | $-1.32 | $-1.53 | $-1.40 | $-0.57 |
| High Forecast | $-0.06 | $-0.13 | $-0.19 | $-0.24 | $-0.26 | $-0.38 | $-0.61 | $-0.60 | $-0.67 | $-0.66 | $-0.66 | $-0.68 | $-0.78 | $-0.73 | $-0.04 | $-0.81 | $-0.83 | $-1.13 | $-1.40 | $-1.32 | $-1.53 | $-1.40 | $-0.57 |
| Low Forecast | $-0.06 | $-0.13 | $-0.19 | $-0.24 | $-0.26 | $-0.38 | $-0.61 | $-0.60 | $-0.67 | $-0.66 | $-0.66 | $-0.68 | $-0.78 | $-0.83 | $-0.04 | $-0.81 | $-1.10 | $-1.13 | $-1.40 | $-1.32 | $-1.53 | $-1.40 | $-0.57 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.00% | 0.00% | 1.01% | 0.71% | 0.90% | - |
According to undefined Wall Street analysts, IGM Biosciences's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to IGMS previous annual EPS of $NaN (undefined).
IGM Biosciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
| PASG | Passage Bio | $0.70 | $6.00 | 757.14% | Buy |
| HOWL | Werewolf Therapeutics | $2.02 | $12.00 | 494.06% | Buy |
| BDTX | Black Diamond Therapeutics | $5.40 | $14.75 | 173.15% | Buy |
| IGMS | IGM Biosciences | $9.31 | $25.00 | 168.53% | Buy |
| MLYS | Mineralys Therapeutics | $11.23 | $30.00 | 167.14% | Buy |
| ERAS | Erasca | $2.86 | $7.00 | 144.76% | Buy |
| STOK | Stoke Therapeutics | $14.70 | $33.33 | 126.73% | Buy |
| DSGN | Design Therapeutics | $4.67 | $9.67 | 107.07% | Buy |
| CGEM | Cullinan Oncology | $17.98 | $32.00 | 77.98% | Buy |
| RNA | Avidity Biosciences | $40.46 | $50.00 | 23.58% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $41.84 | $51.20 | 22.37% | Buy |
| IKNA | Ikena Oncology | $1.69 | $1.33 | -21.30% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |
| GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |
IGMS Forecast FAQ
Is IGM Biosciences a good buy?
Yes, according to 2 Wall Street analysts, IGM Biosciences (IGMS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of IGMS's total ratings.
What is IGMS's price target?
IGM Biosciences (IGMS) average price target is $25 with a range of $12 to $37, implying a 168.53% from its last price of $9.31. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will IGM Biosciences stock go up soon?
According to Wall Street analysts' prediction for IGMS stock, the company can go up by 168.53% (from the last price of $9.31 to the average price target of $25), up by 297.42% based on the highest stock price target, and up by 28.89% based on the lowest stock price target.
Can IGM Biosciences stock reach $14?
IGMS's average twelve months analyst stock price target of $25 supports the claim that IGM Biosciences can reach $14 in the near future.
What is IGM Biosciences's current price target trend?
2 Wall Street analysts forecast a $18.5 price target for IGM Biosciences (IGMS) this month, up 98.71% from its last price of $9.31. Compared to the last 3 and 12 months, the average price target increased by 98.71% and increased by 104.08%, respectively.
What are IGM Biosciences's analysts' financial forecasts?
IGM Biosciences's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $79.57M (high $79.57M, low $79.57M), average EBITDA is $15.91M (high $15.91M, low $15.91M), average net income is $-111M (high $-111M, low $-111M), average SG&A $1.16B (high $1.16B, low $1.16B), and average EPS is $-1.839 (high $-1.839, low $-1.839). IGMS's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $234.99M (high $234.99M, low $234.99M), average EBITDA is $47M (high $47M, low $47M), average net income is $-37.149M (high $-37.149M, low $-37.149M), average SG&A $3.43B (high $3.43B, low $3.43B), and average EPS is $-0.615 (high $-0.615, low $-0.615).
Did the IGMS's actual financial results beat the analysts' financial forecasts?
Based on IGM Biosciences's last annual report (Dec 2023), the company's revenue was $2.13M, which missed the average analysts forecast of $3.81M by -44.17%. Apple's EBITDA was $-263M, missing the average prediction of $762.96K by -34631.29%. The company's net income was $-246M, missing the average estimation of $-294M by -16.08%. Apple's SG&A was $50.07M, missing the average forecast of $55.72M by -10.14%. Lastly, the company's EPS was $-0.0047, missing the average prediction of $-4.858 by -99.90%. In terms of the last quarterly report (Sep 2023), IGM Biosciences's revenue was $509K, missing the average analysts' forecast of $838.33K by -39.28%. The company's EBITDA was $-66.76M, missing the average prediction of $167.67K by -39917.26%. IGM Biosciences's net income was $-61.989M, missing the average estimation of $-68.14M by -9.03%. The company's SG&A was $12.51M, beating the average forecast of $12.25M by 2.14%. Lastly, the company's EPS was $-0.001, missing the average prediction of $-1.127 by -99.91%